tiprankstipranks
Mineralys Therapeutics, Inc. (MLYS)
NASDAQ:MLYS
US Market
MLYS
Mineralys Therapeutics, Inc.
RESEARCH TOOLSreports
Want to see MLYS full AI Analyst Report?

Mineralys Therapeutics, Inc. (MLYS) Stock News & Sentiment

589 Followers
Mineralys Shareholders Approve Directors and Auditor at Meeting
Premium
Company Announcements
Mineralys Shareholders Approve Directors and Auditor at Meeting
3d ago
8K
MLYS
Mineralys: Buy Rating Reiterated on Superior Lorundrostat Profile vs. Baxfendy and Unchanged $42 Price Target
Premium
Ratings
Mineralys: Buy Rating Reiterated on Superior Lorundrostat Profile vs. Baxfendy and Unchanged $42 Price Target
7d ago
MLYS
Mineralys Therapeutics Maps Path After Lorundrostat NDA
Premium
Company Announcements
Mineralys Therapeutics Maps Path After Lorundrostat NDA
18d ago
MLYS
Mineralys: Advancing Lorundrostat Toward Commercialization in Uncontrolled Hypertension With Differentiated Efficacy and Safety
Premium
Ratings
Mineralys: Advancing Lorundrostat Toward Commercialization in Uncontrolled Hypertension With Differentiated Efficacy and Safety
2M ago
MLYS
Mineralys Therapeutics Charts Path After NDA Acceptance
Premium
Company Announcements
Mineralys Therapeutics Charts Path After NDA Acceptance
2M ago
MLYS
MLYS Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
MLYS Upcoming Earnings Report: What to Expect?
3M ago
MLYS
Mineralys Reports Mixed Phase 2 Results for Lorundrostat
Premium
Company Announcements
Mineralys Reports Mixed Phase 2 Results for Lorundrostat
3M ago
8K
MLYS
More MLYS News >

MLYS News on the Web

Mineralys Shareholders Approve Directors and Auditor at Meeting
TipRanks News
Neutral
Mineralys Therapeutics Inc Annual Shareholders Meeting Transcript
GuruFocus News
Neutral
Mineralys Therapeutics Stock Surges on Trial Hopes
TipRanks News
Bullish
Mineralys: Buy Rating Reiterated on Superior Lorundrostat Profile vs. Baxfendy and Unchanged $42 Price Target
TipRanks News
Bullish
Guggenheim Keeps Their Buy Rating on Mineralys Therapeutics, Inc. (MLYS)
TipRanks News
Bullish
Mineralys Data Spotlight: New Phase 3 Results Put Lorundrostat at Center Stage for Hard-to-Treat Hypertension and CKD
Market Chameleon
Neutral
Jefferies says Baxfendy approval may be incrementally constructive for Mineralys
TipRanks News
Neutral
Why Mineralys Therapeutics Stock Is Sinking Today
TipRanks News
Bearish

News Score - Last 7 Days

Very Positive
MLYS
Sector Average
Media Buzz
This Week3 articles
Weekly Average4.25 articles
News Sentiment
This Week100%
Sector Average79%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is MLYS’s Media Buzz Sentiment?
3 articles about MLYS were published this week. In an average week, 4.25 articles are published.
    What is MLYS’s weekly average amount of articles?
    In an average week, 4.25 articles about MLYS are published.
      What is MLYS’s News Sentiment?
      100% of articles about MLYS were positive this week, compared to its sector average of 79%.
        Healthcare Stocks that are Trending in the News
        IMVTImmunovant
        ROIVRoivant Sciences
        ADOAnteoTech Ltd
        JUNSJupiter Neurosciences, Inc.
        AFPAFT Pharmaceuticals Ltd.
        Showing the stocks with the most bullish news sentiment over the past week